Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate [0.03%]
生物制剂DMARD初治类风湿关节炎患者单用或联合甲氨蝶呤使用依那西普或阿达木单抗的治疗模式及成本探究
Joseph Tkacz,Mahdi Gharaibeh,Kathryn Henderson DeYoung et al.
Joseph Tkacz et al.
Background: Etanercept (ETN) and adalimumab (ADA) are tumor necrosis factor inhibitors indicated for treatment of moderate to severe rheumatoid arthritis (RA) and are used as monotherapy or in combination with conventiona...
Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden [0.03%]
患者报告的狼疮发作症状与较差的预后和增加的经济负担有关
Patricia Katz,Winnie W Nelson,R Paola Daly et al.
Patricia Katz et al.
Background: Lupus flares significantly contribute to health resource utilization and hospitalizations. Identification of flare activity may be hindered since validated assessment scales are rarely used in clinical practic...
The Authors Respond [0.03%]
作者回复
Quang A Le,Dimittri Delevry
Quang A Le
Funding for the original study referred to in this letter was received through the PhRMA Foundation Value Assessment Challenge Award. The authors have no conflicts of interest to declare.
The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis [0.03%]
siponimod治疗继发进展型多发性硬化有效且具价值
Patricia G Synnott,Lisa M Bloudek,Ravi Sharaf et al.
Patricia G Synnott et al.
Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Sh...
Corrections [0.03%]
更正通知书
Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities [0.03%]
伴有和不伴身体或精神疾病的青光眼患者的医疗负担评估
Michael Serbin,Beth Devine,Joanna Campbell et al.
Michael Serbin et al.
Background: Glaucoma is a collection of eye diseases that damage the eye's optic nerve resulting in vision loss and blindness. Treatment for glaucoma is primarily pharmacologic; however, studies have shown patients have d...
The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition [0.03%]
新药同台竞技难：影响同类适应症药物开展间接比较的主要因素分析
Daniel A Ollendorf,Eunice Kim,Naomi Bridger et al.
Daniel A Ollendorf et al.
No outside funding supported the writing of this letter. Ollendorf reports advisory board and consulting fees from DBV Technologies, EMD Serano, Gerson Lehman Group, and Sarepta Therapeutics, unrelated to the content of this research letter...
Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States [0.03%]
美国1型糖尿病成人患者的年度医疗费用估算
Vijay N Joish,Fang Liz Zhou,Ronald Preblick et al.
Vijay N Joish et al.
Background: Diabetes health care resource utilization (HCRU) studies tend to focus on patients with type 2 diabetes (T2D) or pool patients with T2D and type 1 diabetes (T1D). There is a paucity of recent data on the cost ...
Gannon Vanscoy,Brandeis Seymore,Nivedita Kohli et al.
Gannon Vanscoy et al.
Twenty years ago, the Journal of Managed Care & Specialty Pharmacy published an article titled "The Emergence of Specialty Pharmacy." While the industry was in its relative infancy at the time, the specialty pharmacy model has since grown, ...
The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis [0.03%]
骨质疏松症经济评估中以患者水平建模方法的价值及改进报告的必要性
Mickael Hiligsmann,Jean-Yves Reginster,Stuart Silverman
Mickael Hiligsmann
No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/...